Endocrine therapy (ET) such as tamoxifen and/or aromatase inhibitors reduces the risk of breast cancer recurrence in patients with estrogen receptor positive tumors (60% of breast cancer)2, but is often accompanied by complaints of cognitive impairment (independent of chemotherapy)3–5. Here, ESR1 is linked to breast cancer.